Abstract

Infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) are of significant clinical concern worldwide. Fosfomycin is one of the limited treatment options for CRKP. However, resistance to fosfomycin in CRKP has been observed. In this study, we aimed to investigate the fosfomycin resistance mechanism of CRKP. Fosfomycin-resistant Klebsiella pneumoniae isolates were collected from four medical centers in Taiwan from 2010 to 2018. The genes that contributed to fosfomycin resistance were amplified and sequenced. Carbohydrate utilization assays and mutagenesis studies were performed to determine the mechanisms underlying fosfomycin resistance. Forty fosfomycin-resistant CRKP strains were collected and used for further analysis. Fourteen strains exhibited low-level resistance (MIC = 256–512 mg/dl), while 26 strains showed high-level resistance (MIC ≥ 1,024 mg/dl). Chromosomal fosAKP I91V was detected in 39/40 fosfomycin-resistant CRKP strains. We observed that amino acid substitution of chromosomal fosAKP I91V increased the MIC of fosfomycin by approximately eight folds, and this was the only mechanism elucidated for low-level fosfomycin resistance. Among the 26 high-level resistance strains, fosAKP I91V combined with transporter deficiencies (18/26, 69.2%) was the most common resistant mechanism, and one strain showed transporter deficiency only. Plasmid-borne fosA3 accounted for 27.0% (7/26) of high-level resistance. Various G3P and G6P transporter gene mutations, including three novel single amino acid mutations (glpT E299D, glpT D274V, and uhpC A393V) were detected in 19 strains. No murA mutation was found in this study. Our study highlights the need for new therapeutic agents for CRKP infections in Taiwan.

Highlights

  • The emergence of multidrug-resistant bacteria has raised great clinical concern worldwide, and Klebsiella pneumoniae is one of the most important pathogens that cause several types of healthcareassociated infections (Podschun and Ullmann, 1998; Juan et al, 2019; Nordmann and Poirel, 2019)

  • We aimed to evaluate the mechanisms of fosfomycin resistance in carbapenem-resistant Klebsiella pneumoniae (CRKP) strains in Taiwan

  • KPC was detected in 21 of 40 fosfomycin-resistant CRKP strains, and the remaining 19 strains fosfomycin-resistant CRKP strains had no carbapenemase detected by both genotype and phenotype assay

Read more

Summary

Introduction

The emergence of multidrug-resistant bacteria has raised great clinical concern worldwide, and Klebsiella pneumoniae is one of the most important pathogens that cause several types of healthcareassociated infections (Podschun and Ullmann, 1998; Juan et al, 2019; Nordmann and Poirel, 2019). Carbapenems are considered as the last resort of treatment of multidrug-resistant K. pneumoniae, Fosfomycin Resistance in Klebsiella pneumoniae but an increasing prevalence of carbapenem-resistant K. pneumoniae (CRKP) has been recorded worldwide (Chiu et al, 2013; Logan and Weinstein, 2017). Fosfomycin is a phosphonic acid antibiotic discovered in a fermentation broth of Streptomyces fradiae in Spain (Gadebusch et al, 1992). It inhibits N-acetylglucosamine enolpyruvyl transferase (murA), which is an essential enzyme in the early stage of cell wall synthesis. Fosfomycin-resistant CRKP has been observed, and is a problem in clinical settings (Yang et al, 2019)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call